Traws Pharma, Inc. TRAW
Traws Pharma, Inc. (Nasdaq: TRAW) is an infectious disease drug developer. Its lead program, ratutrelvir (TRX01), is in Phase 2 for COVID-19. Its next catalyst on record is tivoxavir marboxil: resolve FDA clinical hold (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tivoxavir marboxil — resolve FDA clinical hold (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ratutrelvir | COVID-19 | small molecule | Phase 2 |
| narazaciclib | solid tumors | small molecule | Phase 2 |
| rigosertib | EB-associated SCC (investigator-initiated) | small molecule | Phase 2 |
| tivoxavir marboxil | influenza (treatment and prophylaxis) | small molecule | Phase 1 |
Recent results and decisions
- Oct 23, 2026n/a Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC for up to $50 million in aggregate gross purchase price of newly issued common stock.
The Company entered into a Common Stock Purchase Agreement (the 'Purchase Agreement') and a related Registration Rights Agreement (the 'Registration Rights Agreement'), each dated as of October 23, 2026, with Roth Principal Investments, LLC.
Filing - Aug 14, 2026n/a UK MHRA review of the planned Phase 2a human influenza Challenge study led to a request for a revised toxicology package, delaying study start (ex-US regulatory action).
Following feedback from the MHRA on the Company's planned Phase 2a human influenza Challenge study, Traws is preparing an updated toxicology data package.
Filing - Apr 15, 2026positive Phase 2a topline recap: equivalent time to sustained resolution with no viral rebound in PAXLOVID-eligible patients and faster resolution in ineligible patients (HR 1.31, 95% CI 0.78-2.20, p=0.018); final analysis underway.
Ratutrelvir demonstrated equivalent time to sustained treatment resolution with no viral rebounds in PAXLOVID® eligible subjects.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.